Startup Showcase: “Pharnext: Pioneering Pleotherapy for Neurological Diseases”

Revolutionizing Drug Discovery for Orphan and Common Neurological Disorders

Welcome to’ Startup Showcase, where we spotlight companies that are truly making a difference. Today, we introduce you to Pharnext, an advanced clinical-stage biopharmaceutical company based in Issy-les-moulineaux, France. Pharnext is at the forefront of developing novel therapeutics for severe neurological diseases that currently lack effective treatments.

Rewriting the Rules of Drug Discovery

Pharnext was founded in 2007 by eminent scientists, including Professor Daniel Cohen, a pioneer of modern genomics. Recognizing the critical need for effective treatments in neurodegenerative diseases, the team has dedicated their efforts towards orphan and common neurological disorders, areas which are notoriously challenging due to their complex biology.

Central to Pharnext’s groundbreaking approach is Pleotherapy™, an innovative paradigm in drug discovery. This unique methodology leverages extensive genomic data and network pharmacology to systemize new uses for approved drugs. The result is Pleodrug™, novel drug combinations developed at optimal doses for new formulations, aimed at treating neurodegenerative diseases.

Advancements in Pleotherapy and Pleodrug Development

Pharnext’s pioneering Pleotherapy approach represents a significant advancement in drug discovery, offering an innovative route to repurpose existing drugs for the treatment of complex diseases. By understanding the interconnected molecular network underlying diseases, they create synergistic combinations of drugs, leading to a new class of therapeutic, Pleodrug™.

Pleodrugs hold several key advantages over traditional drug development methods. These include improved efficacy, safety, and robust intellectual property protection due to their unique composition. This approach has led to the successful development of PXT3003 and PXT864, both of which have shown promising results in clinical trials for Charcot-Marie-Tooth disease type 1A (CMT1A) and Alzheimer’s disease, respectively.

Keep exploring EU Startups  Is Innovative FinTech Consulting the Way Forward in European Market?

Paving the Way for Future Developments

The success of Pharnext’s Pleodrugs offers hope for the development of effective therapies for a wide range of neurodegenerative diseases. With plans to develop their leading Pleodrug PXT864 for other conditions such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS), Pharnext continues to push the boundaries of what’s possible in drug discovery and neurodegenerative disease treatment.

Pharnext’s innovative approach to drug discovery and their relentless pursuit of cures for neurodegenerative diseases exemplify the spirit of pioneering innovation that we celebrate in our Startup Showcase. Their work provides a beacon of hope for patients around the world affected by these debilitating conditions.

Stay tuned to our next Startup Showcase as we continue to bring you stories of startups that are making a difference.


Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!

Keep exploring EU Startups  Which Catalonian Apps Startups Are Dominating Barcelona's Tech Scene in 2023?
Previous Story

Startup Showcase: “easyOptimize: Reshaping Energy for a Sustainable Future”

Next Story

Startup Showcase: “Peyya: Bridging Traditional Banking with Decentralized Finance”